These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 23866314)

  • 1. Red yeast rice lowers cholesterol in physicians - a double blind, placebo controlled randomized trial.
    Verhoeven V; Lopez Hartmann M; Remmen R; Wens J; Apers S; Van Royen P
    BMC Complement Altern Med; 2013 Jul; 13():178. PubMed ID: 23866314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can red yeast rice and olive extract improve lipid profile and cardiovascular risk in metabolic syndrome?: A double blind, placebo controlled randomized trial.
    Verhoeven V; Van der Auwera A; Van Gaal L; Remmen R; Apers S; Stalpaert M; Wens J; Hermans N
    BMC Complement Altern Med; 2015 Mar; 15():52. PubMed ID: 25879228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Traditional Chinese lipid-lowering agent red yeast rice results in significant LDL reduction but safety is uncertain - a systematic review and meta-analysis.
    Gerards MC; Terlou RJ; Yu H; Koks CH; Gerdes VE
    Atherosclerosis; 2015 Jun; 240(2):415-23. PubMed ID: 25897793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial.
    Becker DJ; Gordon RY; Halbert SC; French B; Morris PB; Rader DJ
    Ann Intern Med; 2009 Jun; 150(12):830-9, W147-9. PubMed ID: 19528562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phytosterols, red yeast rice, and lifestyle changes instead of statins: a randomized, double-blinded, placebo-controlled trial.
    Becker DJ; French B; Morris PB; Silvent E; Gordon RY
    Am Heart J; 2013 Jul; 166(1):187-96. PubMed ID: 23816039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Red yeast rice improves lipid pattern, high-sensitivity C-reactive protein, and vascular remodeling parameters in moderately hypercholesterolemic Italian subjects.
    Cicero AF; Derosa G; Parini A; Maffioli P; D'Addato S; Reggi A; Giovannini M; Borghi C
    Nutr Res; 2013 Aug; 33(8):622-8. PubMed ID: 23890351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A combined natural supplement lowers LDL cholesterol in subjects with moderate untreated hypercholesterolemia: a randomized placebo-controlled trial.
    Barrat E; Zaïr Y; Ogier N; Housez B; Vergara C; Maudet C; Lescuyer JF; Bard JM; Carpentier YA; Cazaubiel M; Peltier SL
    Int J Food Sci Nutr; 2013 Nov; 64(7):882-9. PubMed ID: 23815518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial.
    Goldberg AC; Leiter LA; Stroes ESG; Baum SJ; Hanselman JC; Bloedon LT; Lalwani ND; Patel PM; Zhao X; Duell PB
    JAMA; 2019 Nov; 322(18):1780-1788. PubMed ID: 31714986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HypoCol (red yeast rice) lowers plasma cholesterol - a randomized placebo controlled study.
    Bogsrud MP; Ose L; Langslet G; Ottestad I; Strøm EC; Hagve TA; Retterstøl K
    Scand Cardiovasc J; 2010 Aug; 44(4):197-200. PubMed ID: 20636227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ESSENS dyslipidemia: A placebo-controlled, randomized study of a nutritional supplement containing red yeast rice in subjects with newly diagnosed dyslipidemia.
    Kasliwal RR; Bansal M; Gupta R; Shah S; Dani S; Oomman A; Pai V; Prasad GM; Singhvi S; Patel J; Sivam S; Trehan N
    Nutrition; 2016; 32(7-8):767-76. PubMed ID: 27143594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel, multi-ingredient supplement to manage elevated blood lipids in patients with no evidence of cardiovascular disease: a pilot study.
    Hobbs T; Caso R; McMahon D; Nymark M
    Altern Ther Health Med; 2014; 20(5):18-23. PubMed ID: 25141367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low daily dose of 3 mg monacolin K from RYR reduces the concentration of LDL-C in a randomized, placebo-controlled intervention.
    Heinz T; Schuchardt JP; Möller K; Hadji P; Hahn A
    Nutr Res; 2016 Oct; 36(10):1162-1170. PubMed ID: 27865358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up.
    Vallejo-Vaz AJ; Robertson M; Catapano AL; Watts GF; Kastelein JJ; Packard CJ; Ford I; Ray KK
    Circulation; 2017 Nov; 136(20):1878-1891. PubMed ID: 28877913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Efficacy of the Consumption of the Nutraceutical "Red Yeast Rice Extract" for the Reduction of Hypercholesterolemia in Humans: A Systematic Review and Meta-Analysis.
    Trogkanis E; Karalexi MA; Sergentanis TN; Kornarou E; Vassilakou T
    Nutrients; 2024 May; 16(10):. PubMed ID: 38794691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.
    Thomas GS; Cromwell WC; Ali S; Chin W; Flaim JD; Davidson M
    J Am Coll Cardiol; 2013 Dec; 62(23):2178-84. PubMed ID: 24013058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monascus purpureus-fermented Thai glutinous rice reduces blood and hepatic cholesterol and hepatic steatosis concentrations in diet-induced hypercholesterolemic rats.
    Bunnoy A; Saenphet K; Lumyong S; Saenphet S; Chomdej S
    BMC Complement Altern Med; 2015 Mar; 15():88. PubMed ID: 25880551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy.
    Ballantyne CM; Laufs U; Ray KK; Leiter LA; Bays HE; Goldberg AC; Stroes ES; MacDougall D; Zhao X; Catapano AL
    Eur J Prev Cardiol; 2020 Apr; 27(6):593-603. PubMed ID: 31357887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques.
    Ose L; Reyes R; Johnson-Levonas AO; Sapre A; Tribble DL; Musliner T
    Clin Ther; 2007 Nov; 29(11):2419-32. PubMed ID: 18158082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study.
    Albert MA; Danielson E; Rifai N; Ridker PM;
    JAMA; 2001 Jul; 286(1):64-70. PubMed ID: 11434828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.
    Sullivan D; Olsson AG; Scott R; Kim JB; Xue A; Gebski V; Wasserman SM; Stein EA
    JAMA; 2012 Dec; 308(23):2497-506. PubMed ID: 23128163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.